Peter Gennemark

Adjunct Associate Professor, Docent

My research aims to improve understanding of diabetes and cardiovascular disease and their treatment, by mathematical modelling.

Systems pharmacology 鈥� a pharma industry collaboration

Peter Gennemark (Principal scientist at AstraZeneca, Gothenburg, Sweden) is adjunct senior lecturer at IMT. Peter has an established collaboration in systems pharmacology with Gunnar Cedersund (IMT). His research is directed towards systems pharmacology in the diabetes and cardiovascular disease areas, with the aim of increasing knowledge of biology, disease progression and drug intervention in these areas.

Publications

2026

Oscar Silfvergren, Sophie Rigal, Katharina Schimek, Christian Simonsson, Kajsa P. Kanebratt, Felix Forschler, Burcak Yesildag, Uwe Marx, Liisa Vilen, Peter Gennemark, Gunnar Cedersund (2026) European Journal of Pharmaceutical Sciences, Vol. 227, Article 107648 (Article in journal)

Par Nordell, Rasmus Jansson-Lofmark, Peter Gennemark (2026) Clinical Pharmacokinetics, Vol. 65, p. 571-582 (Article in journal)

2025

Quentin Vicentini, Dennis Hekman, Deepak Bhatt, Rouven Stulz, Mahya Dezfouli, Peter Gennemark, Nicola Guzzi, Naoko Toki, Bojana Lazovic, Carolina Tangemo, Shalini Andersson, Samir EL Andaloussi, Anders Dahlen (2025) Bioconjugate chemistry, Vol. 36, p. 1299-1310 (Article in journal)

2024

Erica B盲ckstr枚m, Alessandro Bonetti, Per Johnsson, Stefan 脰hlin, Anders Dahl茅n, Patrik Andersson, Shalini Andersson, Peter Gennemark (2024) Molecular Therapy - Nucleic Acids, Vol. 35, p. 102133-102133, Article 102133 (Article in journal)

Hamidreza Arjmandi, Kajsa P. Kanebratt, Liisa Vilen, Peter Gennemark, Adam Noel (2024) PLOS ONE, Vol. 19, Article e0310109 (Article in journal)

Research

Illustration of a person holding arms out, and a mirrored version showing internal organs.

Systems Biology

By combining mathematical models, prior knowledge, and experimental data, we unravel biological mechanisms and contribute to the development of new drugs and clinical tools.

Research projects

An illustration with red tones. You see a human in the middle with a screen on both sides.

Knowledge Driven Drug Development

In this project, financed by VR medicine鈥檚 investment in pharmacy, the researchers are working with AstraZeneca to develop a new type of knowledge driven drug development.

Organisation

Department of Biomedical Engineering (IMT)

A national centre for research, PhD studies and graduate studies within biomedical engineering, since 1972.

A monitor displaying health data for a patient.

Division of Biomedical Engineering (MT)

A division for research, education and innovation within the field of biomedical engineering.